Nitrated oleic acid up-regulates PPARgamma and attenuates experimental inflammatory bowel disease.

[1]  B. Freeman,et al.  Detection and quantification of protein adduction by electrophilic fatty acids: mitochondrial generation of fatty acid nitroalkene derivatives. , 2009, Free radical biology & medicine.

[2]  M. P. Cole,et al.  Nitro-fatty Acid Metabolome: Saturation, Desaturation, β-Oxidation, and Protein Adduction* , 2009, Journal of Biological Chemistry.

[3]  K. Nettles.  Insights into PPARγ from structures with endogenous and covalently bound ligands , 2008, Nature Structural &Molecular Biology.

[4]  Y. E. Chen,et al.  Molecular recognition of nitrated fatty acids by PPARγ , 2008, Nature Structural &Molecular Biology.

[5]  J. Ellenberg,et al.  Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. , 2008, Gastroenterology.

[6]  T. A. Richardson,et al.  Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. , 2008, Cell metabolism.

[7]  Mark T. Gladwin,et al.  The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics , 2008, Nature Reviews Drug Discovery.

[8]  B. Freeman,et al.  Nitro-fatty Acid Reaction with Glutathione and Cysteine , 2007, Journal of Biological Chemistry.

[9]  T. Sobko,et al.  Protection from nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers by dietary nitrate. , 2007, Free radical biology & medicine.

[10]  A. T. Te Velde,et al.  The PPARγ Agonist Rosiglitazone Impairs Colonic Inflammation in Mice with Experimental Colitis , 2007, Journal of Clinical Immunology.

[11]  Jifeng Zhang,et al.  Nitrated Fatty Acids: Endogenous Anti-inflammatory Signaling Mediators* , 2006, Journal of Biological Chemistry.

[12]  T. Okanoue,et al.  Interferon‐gamma is causatively involved in experimental inflammatory bowel disease in mice , 2006, Clinical and experimental immunology.

[13]  X. Thuru,et al.  PPARγ as a new therapeutic target in inflammatory bowel diseases , 2006, Gut.

[14]  W. Tremaine,et al.  American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.

[15]  Y. Chen,et al.  Fatty Acid Transduction of Nitric Oxide Signaling , 2005, Journal of Biological Chemistry.

[16]  K. Morimura,et al.  Peroxisome proliferator activated receptor γ in colonic epithelial cells protects against experimental inflammatory bowel disease , 2005, Gut.

[17]  G. Rogler,et al.  Significance of anti-inflammatory effects of PPARγ agonists? , 2005, Gut.

[18]  J. Auwerx,et al.  Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-γ , 2005, The Journal of experimental medicine.

[19]  Jifeng Zhang,et al.  Nitrolinoleic acid: An endogenous peroxisome proliferator-activated receptor γ ligand , 2005 .

[20]  J. Bassaganya-Riera,et al.  Activation of PPAR γ and δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease , 2004 .

[21]  B. Freeman,et al.  Red cell membrane and plasma linoleic acid nitration products: synthesis, clinical identification, and quantitation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Jeff A. Cole,et al.  Nitrate, bacteria and human health , 2004, Nature Reviews Microbiology.

[23]  S. Nakagawa,et al.  A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. , 2003, Gastroenterology.

[24]  H. Aburatani,et al.  Peroxisome Proliferator-Activated Receptor Gamma Agonist Ligands Stimulate a Th2 Cytokine Response and Prevent Acute Colitis , 2002, Inflammatory bowel diseases.

[25]  P. Di Mascio,et al.  Characterization of linoleic acid nitration in human blood plasma by mass spectrometry. , 2002, Biochemistry.

[26]  E. Furth,et al.  An open-label trial of the PPARγ ligand rosiglitazone for active ulcerative colitis , 2001, American Journal of Gastroenterology.

[27]  J. Herrerias,et al.  Mediterranean diet and health: biological importance of olive oil. , 2001, Current pharmaceutical design.

[28]  J. Auwerx,et al.  Attenuation of Colon Inflammation through Activators of the Retinoid X Receptor (Rxr)/Peroxisome Proliferator–Activated Receptor γ (Pparγ) Heterodimer , 2001, The Journal of experimental medicine.

[29]  J. Lu,et al.  Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. , 2000, The American journal of pathology.

[30]  M. Lazar,et al.  A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. , 1999, The Journal of clinical investigation.

[31]  P. Hellström,et al.  Greatly increased luminal nitric oxide in ulcerative colitis , 1994, The Lancet.

[32]  E. Weitzberg,et al.  Intragastric nitric oxide production in humans: measurements in expelled air. , 1994, Gut.

[33]  S. Barnes,et al.  Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. , 1994, The Journal of biological chemistry.

[34]  E. Weitzberg,et al.  Nitric oxide and inflammation: The answer is blowing in the wind , 1997, Nature Medicine.